1. The emerging therapeutic landscape of relapsed/refractory multiple myeloma

   • Benjamin Tanenbaum
   • Timothy Miett
   • Shyam A. Patel

   Review Article 03 December 2022 Pages: 1 - 11

   

2. Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives

   • H. Miles Prince
   • Martin Hutchings
   • Ranjana Advani

   Review Article Open access 13 December 2022 Pages: 13 - 29

3. Comparison of multiple treatments in the management of transplant-related thrombotic microangiopathy: a network meta-analysis

   • Jingyi Yang
   • Xiaoyan Xu
   • Yue Han

   Review Article 22 December 2022 Pages: 31 - 39

   

4. Excess deaths among adults with sickle cell disease in 2020 compared to prior years

   • Susanna Curtis
   • Billett Henny
   • Minniti Caterina

   Original Article 10 November 2022 Pages: 41 - 44

   

5. Chronic active Epstein-Barr virus infection involving gastrointestinal tract with hemophagocytic lymphohistiocytosis

   • Kai Shen
   • Xiao Shuai
   • Hongbing Ma

   Original Article 19 December 2022 Pages: 45 - 53

   

6. Comparison of clinical characteristics of first-episode thrombotic thrombocytopenic purpura and TTP-like syndrome: a retrospective cohort study in a level I hematology center in China

   • Guiying Dong
   • Fang-e Shi
   • Jihong Zhu

   Original Article 17 November 2022 Pages: 55 - 62

   

7. A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy

   • Andrew F. Berdel
   • Raphael Koch
   • Christoph Schliemann

   Original Article Open access 18 November 2022 Pages: 63 - 72

   

8. Integrated single-cell transcriptome analysis of CD34 + enriched leukemic stem cells revealed intra- and inter-patient transcriptional heterogeneity in pediatric acute myeloid leukemia

   • Deepshi Thakral
   • Vivek Kumar Singh
   • Rachna Seth

   Original Article 17 December 2022 Pages: 73 - 87

   

9. Cytogenetic evolution predicts a poor prognosis in acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation

   • Ruiqi Li
   • Ziwei Wang
   • Jianmin Wang

   Original Article 21 December 2022 Pages: 89 - 97

   

10. Monocytosis at the time of diagnosis has a negative prognostic impact in myelodysplastic syndromes with less than 5% bone marrow blasts

    • A. Kasprzak
    • C. Assadi
    • U. Germing

    Original Article Open access 21 November 2022 Pages: 99 - 106

    

11. Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic

    • Ales Obr
    • Katerina Benesova
    • Pavel Klener

    Original Article Open access 11 November 2022 Pages: 107 - 115

    

12. VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience

    • Susanne Ghandili
    • Dzenefa Alihodzic
    • Lisa B. Leypoldt

    Original Article Open access 16 November 2022 Pages: 117 - 124

    

13. Prognostic value of the nutritional risk index in patients with newly diagnosed multiple myeloma

    • Limei Zhang
    • Shuzhao Chen
    • Yun Wang

    Original Article Open access 28 November 2022 Pages: 125 - 132

    

14. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

    • Mehmet Sinan Dal
    • Bahar Uncu Ulu
    • Tülin Fırat Tuğlular

    Original Article 19 November 2022 Pages: 133 - 140

    

15. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience

    • Lauren D. Curry
    • Reinhold Munker
    • Maxwell M. Krem

    Original Article 11 November 2022 Pages: 141 - 154

    

16. Comparing the efficacy of salvage regimens for relapsed/refractory B-cell acute lymphoblastic leukaemia: a systematic review and network meta-analysis

    • Han-Yu Cao
    • Chao-Ling Wan
    • Sheng-Li Xue

    Original Article 17 November 2022 Pages: 155 - 165

    

17. Bortezomib-based chemotherapy for patients with Waldenström macroglobulinemia: a single-center experience

    • Ziou Liu
    • Shenghua Jiang
    • Xin Cao

    Original Article 14 November 2022 Pages: 167 - 174

    

18. Refractory hepatosplenic T-cell lymphoma was successfully treated with salvage allogeneic hematopoietic stem cell transplantation combined with enhanced myeloablative preconditioning

    • Wenqiu Huang
    • Song Xue
    • Jingbo Wang

    Original Article 10 November 2022 Pages: 175 - 180

    

19. Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation

    • Shahram Mori
    • Mengni Guo
    • Juan Carlos Varela

    Original Article 03 December 2022 Pages: 181 - 190

    

20. Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysis

    • Jorge Garcia Borrega
    • Boris Böll
    • Jan-Michel Heger

    Original Article Open access 17 November 2022 Pages: 191 - 197

    

21. Feasibility of electronic patient-reported outcome monitoring and self-management program in aplastic anemia and paroxysmal nocturnal hemoglobinuria—a pilot study (ePRO-AA-PNH)

    • Silas Bänziger
    • Kimmo Weisshaar
    • Beatrice Drexler

    Original Article Open access 03 November 2022 Pages: 199 - 208

    

22. Remission of universal vitiligo after allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome

    • Yingying Zhai
    • Qingyuan Wang
    • Song Jin

    Letter to the Editor 15 November 2022 Pages: 209 - 210

    

23. Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms

    • Bahga Katamesh
    • Ahmad Nanaa
    • Aref Al-Kali

    Letter to the Editor 04 November 2022 Pages: 211 - 212

    

24. Feasibility of autologous peripheral blood stem cell mobilization and harvest in adult patients with FLT3-mutated acute myeloid leukemia receiving chemotherapy combined with midostaurin: a single-center experience

    • Stefano Cordella
    • Angelica Parisotto
    • Fabio Forghieri

    Letter to the Editor 20 October 2022 Pages: 213 - 217

25. Impact of tablet crushing on the dissolution of venetoclax

    • Takeo Yasu
    • Eri Hikita
    • Mikio Shirota

    Letter to the Editor 04 November 2022 Pages: 219 - 220

    

26. Escalation to high‐flow nasal cannula oxygen in hematological malignancy: the right choice at the right moment?

    • Pasquale Buonanno
    • Giuseppe Servillo
    • Antonio Matias Esquinas

    Letter to the Editor 09 November 2022 Pages: 221 - 222

27. Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma

    • Kohei Shinmura
    • So Okubo
    • Tomonori Nakazato

    Letter to the Editor 17 November 2022 Pages: 223 - 225

    

28. A neonatal case of congenital blastic plasmacytoid dendritic cell neoplasm with KMT2C gene duplication

    • Jian Li
    • Jun Wang
    • Yongjun Fang

    Letter to the Editor 09 November 2022 Pages: 227 - 229

    

29. CD19 CAR T-cell infusion during severe COVID-19 acute respiratory distress syndrome in large B-cell lymphoma

    • Nina Buchtele
    • Philipp Wohlfarth
    • Philipp B. Staber

    Letter to the Editor 18 November 2022 Pages: 231 - 234

    

30. New-onset Evans syndrome in a patient with SLE post SARS-CoV2 mRNA vaccination

    • Timothy Y. M. Ng
    • Winnie Z. Y. Teo
    • Gim Gee Teng

    Letter to the Editor 12 November 2022 Pages: 235 - 236

31. Platelet recovery with ibrutinib therapy in patient with treatment-refractory immune thrombocytopenia

    • Paul Christopher Parish
    • Donald C. Moore
    • Richard Cambareri

    Letter to the Editor 28 November 2022 Pages: 237 - 238

32. Mutations in the plasma cell clone identify mechanism of polyneuropathy in a case of POEMS syndrome associated with Castleman disease and multiple myeloma

    • Annamaria Brioli
    • Antje Wyrwa
    • Karin G. Schrenk

    Letter to the Editor Open access 19 November 2022 Pages: 239 - 242

    

33. Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma

    • Yosuke Masamoto
    • Arika Shimura
    • Mineo Kurokawa

    Letter to the Editor 11 November 2022 Pages: 243 - 244

    

34. Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab

    • Tim Strüßmann
    • Johannes Jung
    • Reinhard Marks

    Letter to the Editor Open access 17 November 2022 Pages: 245 - 247